These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8334769)

  • 1. [Pulse-dose cyclophosphamide therapy for chronic progressive multiple sclerosis].
    Watanabe T; Yamamoto T; Saito T; Sugano M; Tsukamoto T
    Rinsho Shinkeigaku; 1993 Jan; 33(1):15-20. PubMed ID: 8334769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pulse-dose cyclophosphamide therapy for steroid-refractory autoimmune neurological diseases].
    Watanabe T; Shimoji S; Sugiyama Y; Tsukamoto T; Yamamoto T
    Rinsho Shinkeigaku; 1995 Jun; 35(6):611-6. PubMed ID: 8521635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS.
    Smith D
    J Neurol Sci; 2004 Aug; 223(1):73-9. PubMed ID: 15261565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
    Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
    N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of systemic diseases with pulse cyclophosphamide: 15 cases].
    Amoura Z; Choukroun G; Royer I; Gayraud M; Guillevin L
    Ann Med Interne (Paris); 1990; 141(5):416-20. PubMed ID: 2256584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
    Zephir H; de Seze J; Duhamel A; Debouverie M; Hautecoeur P; Lebrun C; Malikova I; Pelletier J; Sénéchal O; Vermersch P
    J Neurol Sci; 2004 Mar; 218(1-2):73-7. PubMed ID: 14759636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
    Carter JL; Hafler DA; Dawson DM; Orav J; Weiner HL
    Neurology; 1988 Jul; 38(7 Suppl 2):9-14. PubMed ID: 2838768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The course and prognosis of mesangioproliferative glomerulonephritis].
    Shilov EM; Tareeva IE; Ivanov AA; Troepol'skaia OV; Krasnova TN; Varshavskiĭ VA; Proskurneva EP; Ivanova LV; Khudova IIu; Miroshnichenko NG
    Ter Arkh; 2002; 74(6):11-8. PubMed ID: 12136475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment on intermittent intravenous cyclophosphamide pulse therapy in diffuse proliferative lupus nephritis].
    Okubo T; Ideguchi H; Ihata A; Nakamura M; Ueda A; Ohno S; Hagiwara E; Aoki A; Shirai A; Ishigatsubo Y
    Ryumachi; 2000 Jun; 40(3):605-11. PubMed ID: 10920685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis.
    Perini P; Gallo P
    J Neurol; 2003 Jul; 250(7):834-8. PubMed ID: 12883926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
    Dawson DM; Carter JL; Hafler DA; Weiner HL
    Riv Neurol; 1987; 57(2):88-91. PubMed ID: 3039645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
    Rinaldi L; Perini P; Calabrese M; Gallo P
    Neurol Sci; 2009 Oct; 30 Suppl 2():S171-3. PubMed ID: 19882369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1988; 22(5):399-403. PubMed ID: 2854886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia.
    Smith DR; Balashov KE; Hafler DA; Khoury SJ; Weiner HL
    Ann Neurol; 1997 Sep; 42(3):313-8. PubMed ID: 9307252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients. One year follow-up.
    Bergamaschi R; Versino M; Raiola E; Citterio A; Cosi V
    Acta Neurol (Napoli); 1993 Feb; 15(1):33-43. PubMed ID: 8456594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report.
    Nozaki K; Abou-Fayssal N
    J Neurol Sci; 2010 Sep; 296(1-2):121-3. PubMed ID: 20579663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.